#
- .-$+/$*)
+$*$
+$ ($=
-$.$.
:
++*-/0)$/4

()
>
$ 0;

..$./)/
-*! ..*-
)$1 -.$/4
*!
'$!*-)$
@
)
-)$.*

$)
)" ( )/
 )/ -

$- /*-
*!
0/
$)
 -1$ .
-()>)$ 0Q0.!>Q 0

+$ ($B !!
% $ '  -  ' $. . S /#.  /#
/ 0( -
*!
 /#.
 '/
/*
+$*$ .
L @UTM
$)
/#

VTUY $& '1$1$-$  G'1$1$-0. Z aT>TU^B )$/
// .
!-*(
VTTT@VTUX
 )/ -.
!*-
$. .
*)/-*'
:
- 1 )/$*) VTUX *' $'*1$-$  G*'1$-0. UU;WUZ [T^

VTTV 
*-*)1$-$  G [[Y ]>Z^  1 -
0/

*-*)1$-0.  .+$-/*-4
4) -*(.+$-/*-4
4) -*( /0-'
)
 ($@4)/# /$

 /-*1$-$  G )/$1$-0. U]Y]@ G  W];TTT;TTT YT^ +$*$ . -*$) -/#*(43*1$-0.G U]U\ UU
)90 )5 )90 )5
 [Y;TTT;TTT V>Y^

VTUX +$*$ . V\;ZX[
L))0(M >TT]^  /# *) 4)/# /$.

*-'
'/#
-")$5/$*)
*((0)$'
$. .
0-1 $'')
)
 .+*).
@
$&
>

N )*($)/*-
./$''
0) / -($)
!*-
 /#
/
*-'
'/#
-")$5/$*)
*((0)$'
$. .
0-1 $'')
)
 .+*).
@



.$
/
# />

#//+=GG222> >"*1G.-.G*0/G!.@.-.>#/('
*-'
'/#
-")$5/$*)
*((0)$'
$. .
0-1 $'')
)
 .+*).
@
*'>

#//+=GG222>2#*>$)/G( $ )/- G!/.# /.G!.UTWG )G
+$ ($B #
/$*)'
$/'
//$./$.
4./ (;
*-/'$/4
$' ;
0. .
/#
 -/$7/
/
 /#.
+ -
UTT;TTT
+ *+'
$)
!!
% $ ' /*
0$'
)/$*)@' 1 '
.//$./$.
*)
0. .
*!
(*-/'$/4>




#
/#
)$/
// .

 
 ( 

(-

- ) .
-
(*-
$(+*-/)/
/#)
/0'
)0( -.
!-*(
VTTT@VTUX
 )/ -.
!*-
$. .
*)/-*'
:
- 1 )/$*) 0
/*
/#
*(+' 3$/4
*!
+*$.*)$)"
/#.>

#'' )" .
3$./
2# )
$/
*( .
/*
*($)/$*)
*!
-0".;
+0-+*. ;
0) -'4$)"
*) $/$*);
)
0)&)*2).>


/0-'
)

 ($@4)/# /$

*0
)
0.


/*
'**&
0+
/# .
/>

+$*$ .

-*$)

=

 /#.
-
'..$7
0.$)"
/#
)/ -)/$*)'
'..$7/$*)
*!
$. . .;
 )/#
 1$.$*)
L @UTM>
-0"
+*$.*)$)"
/#.
-
$ )/$7
0.$)"
0) -'4$)"
0.
*!
/#
* .
XT@XX;
ZT@ ZX;
\Y;
)
UT@UX>
#
!*''*2$)"
(0'/$+'
0.
*!
/#
* .
2 -
0.
/*
$ )/$!4
.+ $7
4)/# /$. -0"
/4+ .=
XT>V
!*-
)/0-'
)
. ([email protected])/# /$
*+$*$
)'" .$.;
XT>W
!*-
( /# *) ;
XT>X
!*-
.4)/# /$
*+$*$
)'" .$.
3'0 $)"
( /# *) ;
XT>U
!*-
# -*$);
)
XT>T;
XT>U;
XT>V;
XT>W;
 /# *) XT>X
*-
XT>Z
!*-
)4
*+$*$ >
++-*3$(/ '4
*) @7!/#
*!
-0"
+*$.*)$)"
/#.
'&
$)!*-(/$*)
*)
/#
.+ $7
-0".
$)1*'1 >
*(
*!
/# .
/#.
(4
$)1*'1
*+$*$
)'" .$.
*-
# -*$)>
" @  %0./
/#
-/ .
2 -
'0'/
0.$)"
/#
$- /
( /#*
)
/#
VTTT
./) -
+*+0'/$*)>

+$ ($B % $ 
$&(! (-
J .+$-/*-4
 +- ..$*)
&  #
 J-0(

5

"6
-3  
>

5 
6
- J0$$
J--#4/#($
J (+$-( )/
2#$'
*+ -/$)"
(#$) -4
#(&'
$&
 ''
$#(&$!
#
&*#( $#
45
#(&'
$&
 ''
$#(&$!
#
&*#( $# 45
J )/-1 )*0.
-0"
0.
'  $)"
/*
'**
,


 *
 
!*


!

 


  
*-)
+/#*" )
/-).($..$*)

"
#

%
$ 


! 


 J 
J +/$/$.

J +/$/$.


,$&
 ( $#& '1
,$&
 ( $#& '1 % $ 
$&  (-
,

J.4#$/-$
86

# 
!


 !
  


! %


J $/$*)
@
-*$)
$.
'$(
/*

/#
(*./
 $/$1
.0./)
 !
-
J0$$ '
/$*)
J +- ..$*)
96

!*
# 
!


 !
! 
-
J)3$ /4
J$))$'
/- ..
J#4.$'
J$/# -2'.
J 4+ -'" .$
J*)./$+/$*)

?./ - */4+ .
2$''
#$(
# '+
4*0
7"0-
*0/
2#*
/# .
+ *+'
- ? !)&&
#'!)&&
##'

HeHHeaHealtheallth PrescribedPreesscribed IllIlIIllicitlllliicit DDruDrugg CareCarCaarre OpiOOpOpioidp oidod OpiOpioidoid DeaDealerler ProviderProPrProrovidvviidder

#//+=GG222> >"*1G$/'$").G+ !GVTUU@UU@1$/'.$").>+ !

) ($B 
 !#(
% " 
 !#(
% "  *( *)
*/$).
 ..
/*
)
*+$*$ >
*( *)
0. .
)
*+$*$ >

/
$.
)
$''$$/
/
.*
/# 4
& +
$/
,0$ />
# )
/# 4
$ ;
/#
!($'4
$.
(--.. ;
.*
/# 4
& +
$/
,0$ />

#
)0( -.
.'*2'4
$)- . >
$''
/#$.
*0)/-4
& +
,0$ /B ( -$)
+$ ($

J( -$).
*)./$/0/
X>Z^
*!
/#
2*-' D.
+*+0'/$*)
)
*).0(
++-*3$(/ '4
\T^
*!
/#
2*-' D.
*+$*$ .>
J( -$).
*).0(
]]^
*!
/#
2*-' D.
#4 -** *)
J# -
-
)*0"#
+- .-$
*+$*$ .
!*-
#
( -$)
/*
/&

+- .-$+/$*)

 


B *+$*$
1 -4
X
#*0-.
!*-

(*)/#>

J./$(/
V>U
($''$*)
( -$).
2$/#
+- .-$+/$*)
*+$*$
.0./)
0.
$.*- -
$)
VTUV
J./$(/
XZ[;TTT
 $/
/*
# -*$)
$)
VTUV>

J4
''
+0'$
# '/#
( .0- .
*!
*0/*( .
- '/
/*
+$);
2
-
)*/
.0+ -$*->

( -$)
*$ /4
*!
)/ -1 )/$*)'
$)
#4.$$).
L M
)#$&)/$;
$)
#4.$$)
/$*)'
)./$/0/
*)
-0"
0.
L M



 


  =
WTTT
@
VTTT

 

 
   
   

XTTT@WTTT
 UYTT
 T UYTT U\T]

*".#$- ;
$(>
+$0(
!*-
/#
.. .>

-1 ./$)"
/0- D.
 ./
$)
 $/$*) -*2)./ $)
 >


-$ !
$./*-4
*!
+$/ .;
+$*$
 +/$ .;
)
+$*$
  +/*-.>

-*
/$*)'

$
LM>

0)
U]]W>



 


  =
U\TT@U][W $.*1 -4
*!
/#
) *" )*0.
+$*$
4./ (>
U][W>  @           
     u d k nociceptin

 
 
 
   
       
    Endogenous Endorphin Enkephalin Dynorphin Nociceptin Ligand

Morphine Exogenous Methadone Deltorphin Buprenorphine U\T] U\XX Agonist U\]\U]UV U]W] U][W Fentanyl U]TZ U][T U]UX Exogenous Naloxone >>
  Naloxone Naloxone >>





Antagonist Naltrexone 
 LM  
 
   
 
 )4 -
;
./ -)&
>
$./*-$'
 1$ 2=
+$*$
-  +/*-.>
 ''>
+-$'
VTTW>
LVXM
X=U]\@VTY>
-*2)./ $)
 >


-$ !
$./*-4
*!
+$/ .;
+$*$
 +/$ .;
)
+$*$
  +/*-.>

-*
/$*)'

$
LM>

0)
U]]W>

 )
=

-*+$* ')**-/$) /( %($&' $# '(' #($# '('

#!' 
)%&'% #! 0; ;& )'" .$ )*
6 /

#!' 
% #! 0; ;& )'" .$ )*
6 /

'% &($&-
)#( $# 0 - . )*
6 /

'(&$ #('( #!
&( 0;& - . )*
6 /

'-$($" "' ' & $)- . )*
6 /

 # 0; ;& $)- . - .

( $# 0;& $)- . )*
6 /

&$!( # 0 $)- . - .

&$+(
$&"$# 0G $)- . - .

!!&6'
#'(' 0
$!)"'
8
#
90
=(
 ( $#2
4
*)'
>
$'' -;
>>
L $/*-M;
-.
>
-$&..*);
>>;
#>>;

>
' $.# -;
>>;
)$)
>
$ ) -@ -*)$.#;
>>;
)
$''$(
>
*0)";
>>
L..*$/
 $/*-.M>
#$' '+#$;
#0-#$''
$1$)"./*) ;
VTT]>
" .=
W;T\X
L1*'0( .
U
)
V
*($) M>


 


  =
U][T@VTUZ 

 


  =
VTTT@VTUZ 
 


 

 
 
  

  @       
  
 /*
  

!-*(


 
Y/#
 
  
  
    
    

U][W U][] U]\Z U]]Z VTT[ VTTT VTT[ VTUT VTUX  
U][T  
 >>
 

  


Y/#
 
  LM  
  



$ 0;
() /$*)'
*.+$
:
''$/$1
-
-")$5/$*)>

#//+=GG222>)#+*>*-"G#$./*-4@#*.+$+GGG+"G4+ @-
$ 0;
()  

-0"
)!*- ( )/
" )4
LM
# 0'

)$/$/
$)
U][W
4
- .$ )/
$3*)>


-0".
#)"
'.. .
!-*(
/$(
/*
/$( >

#$.
$.
/#
VTUZ
# 0' >

# 0' -$/ -$ 3(+' .  =
)/0-''4
*0--$)"

'&'*$ .
.0#
.
(*-+#$)
*-
*
( $'
0. <
#$"#
* $) >


-*$);
-$%0);
  $/$*)
+*/ )/$'

  =
  =
.-$.-$$ .
.

*(+*0) .
/#/
2*-&
/
/#
*(+*0) .
/##/
2*-&&
/ /#
*
*+$*$
+$$*$$  $'
0. <
#$"#
 $/$*)
*-+#$) ;
34* *) ;
 /# *) ;

-  +/*-.
+/*-.
+*/ )/$'  )/)4';
4 -** *)

 $'
0. <
(* -/
0+- )*-+#$) ;
 /($)*+# )G

 
L  L-
!MM=
*-$"$)''4
0.$ $ ''
/*
.-$$
.'' +@  $/$*)
+*/ )/$' * $) ;
/($) $) 0$)"
( $/$*).;
/# )
*+$*$ .;
0/
)*2
$.


/ -(>  $'
0. ;
'*2
0.
  )5* $5 +$) .;
-$.*+-* *';
+*/ )/$'

 $'
0. <
'*2
0.
*$/0..$)
;
# ) -")
2$/#
 +*/ )/$' * $)

- .*/;
;
//
;
+$*$
#-(*'*"4;
$)
#4.$$)
*0-)';
VTT\
*'
) ./# /$
!

#0()
 $)"
/**&

*.
)
#

- .+*). ;
$/
$)! -.
/#/
*$)
/$(0')/.
// )/$*)
)
 /#(+# /($) E++ -.F #0()
 $)"
#.
)
) *" )*0.
.4./ (
/#/
$.
6 /
4
/#/
& !0') .. .0./) >

# - !*- ;
/# -
(0./


- .*)
!*-
$/>


) ./# .$
G /($)
''0$)*" )$. 
-0".
#1
/#
+*/ )/$'
!*-
#-(
)
/#
+*/ )/$'
!*-
"** >

 4*/
 +- ..$*) 

'*#*'
 /$1 G )3$ /4
-$/0-/ .
4+)*/$.
 /$*)
 )5* $5 +$) . E*2) -.F ) ./# .$

# *.$.
!$/

*.
(& .
*-+#$)
)'" .$
-*$)
+$*$ . $--# 
/#1 )
+*$.*) )0(  )/)4'
*0"# 34* *)

0. 
-$%0) ))$)*$ . ++ /$/
)'" .$ - '.0.>
/# -
*!
*3$*'*"4>

UYW\>

-*$)
`
$ /4'(*-+#$)
LM
`
$(*-+#$)  $/$*) #4.$'
#-(  + ) ) *$'
#-( 4)/# .$5 
$)
U\[X
L>>
' ) 0/ #-*)$   )-
-$"#/M

' .0- .4#*'*"$'
#4.$'
 ) )/*3$/$*) *$'
#-( '/#@-
L.#*-/
7)$/$*)M=

 


%*

  


#*
 " *
%

 1 '*+
$)
U\]\
4
4 -
#-( 0/$'
L + ) ) +$)-$#
- ) ) . -G *./.  
! %-
% ! 

 
!


  
*
 %*

&$ # VK[\ VK\ VKY WKT WKTT WKT WKT WKT VKYX UKZ WKT WKT  '$3
*6()M
2$/#
/#
"*'
*!
+-*1$ $)"
)'" .$
)

 !
   -


) 


"!
 %
! !
#
3
$ # VKWW VKT VKT WKT VKW] WKT VK\ UKW VKU[ UK\ VKY VKW 
%
! 
! 

 
" -
& ()&('*0"#
.0++-VKVW ..$*)
2$/#*0/
 $/$*)>


VKW UK] VKY VKTU VKT VKV UK\ VKTT VKX UK] UK[ (&(
"($# UK\Z VKY UK[ UKX VKT\ UK\ VKW VKW UK\[ UKZ UK] VKT  

 &
%
 %

   %
 *


"
 *
!$$! -*$);
!-*(
UKXT UK]-*$.#
L VKX  -()M
`
./-*)";
# UK]W VKW UK] -*$ UKZ VKVU VKV VKX VKU "*
 
 

(

# 
0
"

  
(" # VKTT VKU UK[ VKU UKYX UK] UK[ UKT UKZ] VKT UKY UKY    *


% ! 
 
  -

 

   *
 
 
#.$ .% #'0-- )/'4;
/#UKZW
(%*-$/4
*!
# UKY UK[ UK\ UK\W-*$)
*( UK[ VKU.
!-*(
UK\ UKZY VKT UKY UKY ""
%

 

 -
 !
 



"%
 "  *
"%(" # UK\U UKW UK\ VKX UKZ[ VKT UK] UKU UKYT UKX UKY UKZ  

 "


 !

  %

 !
  $$!"#)$./);
-);
0-(;
#$') ;
$UKVX TK] VK] T VKVU VKW VKZ /)(;
 UK\ 3$*;
UKXV TK\ UKU VKX )%&#$&% #)
*'*($UKZT UKV UKW VKW UKZX VKT UKY UKY UKX] UKZ UKY UKX ## ' TK]] TK] VKU T UKYU UK] UK[ TK\ UKYT UK[ UKW UKY -1$)" *(+0'.$*) *)/-*' *). ,0 ) . $!*#(' /
$.
*).$ UKV\ - ;
/
/#$.
/$( VKU UK[ T UKTU;
/*
 UK[
/# UKV
(*./
 $/$1 TKU
UKYV UK] UKY UKV ;3  UKXX VKV VKU T UKWT UKT UK[ TK\ UKTZ UKV UKT UKT .0./)
*)
-/#>

$*/$)
(4
 ;
0/
/#
#-(.
 UKUW UK[ UKX TKW UKVW VKV UKU TKW UKWV UKZ UKW UKU 
''
#1
.+ /.
*!
/#$.
- 2-
.4./ (
$)
*0-. '1 .>

#
*)'4
$6 - )
$.
2# )
/#
$)/ -+'4
(-!%# (..*$/
2$/#
#UKWV UKV -*$)
-UKW UKZ
!-
(*- UKVY UKX
-(/$> UKW UKT TK][ UKU TK\ UKU  /2 )
/#
" ) /$.;
/#
)1$-*)( )/
- /
/#
. //$)".
!*-
 $/$*)>
#$! 
'(&$ ' UKXY TK\ VKT UK[ TK\\ UKU TK\ TK\ UKUW UKW TK\ UKW J# -
$.

7)
'$)
 /2 )
)
 $/
)

)*)@ $/>
  TK\Z UKX UKV T UKU] UKX UKU UKU UKWT UKX UKW UKV J'$($)/$)"

.0./)
2$''
)*/
'$($)/
 $/$*)>

 0$)"
+- .-$
*+$*$ .
$.
$(+*-/)/;
'('- UKTY UKZ UKZ T UKUW UKY UKV TK[ UKT] UKV UKT UKU 0/
2$''
'$& '4
' 
/*
E/#
) 3/
/#$)">F
! -!
# (& (' TK]W UKZ TK] TKW TK\[ UKZ TK[ TKW TK][ TK\ TK[ UKX J#$.
$.

#-*)$
$. .
)
) .
#-*)$
- > 222># -*$)>) /
#//+.=GG ( )>2$&$+ $>*-"G2$&$G TKYT -*$)
TKW UKV T UKTX UKZ UKV TKW TK\Y TK[ UKU TK\ 0//;
>;
$)";
>
>;
0'.0-4;
>
:
'& (*- ;
>
 1 '*+( )/
*!

-/$*)'
.'
/*
.. ..
/#
#-(
*!
-0".
*!
+*/ )/$'
($.0. >

5 *
6
:<>0
UTX[HYW
LVTT[M> #//+=GG222>.(>*-"G,0'$/4@+-/$ G 7)$/$*)@*!@ $/$*) #
$.
*!
$"
#-( #
( -$)
/$ )/@*/*-
 '/$*).#$+
LVT/#
/*
VU./
 )/0-4M 4(*)
&' - E0.
- .$./)/F 2.0$/ SUZ E' ..
 $/$1 F     U]]Z VTT[ VTUT VTUY RZTT;TTT;TTT [Z^
*!
# -*$)
0. -.
./-/
2$/#

+- .-$+/$*)
*+$*$ >
RW;TTT;TTT;TTT

E *2
/#
( -$)
*+$/
+$ ($
2.
./-/
4
*)
+#-( 0/$'
*(+)4>F
#
 &>

-#
X;
VTUY>
RWY;TTT;TTT;TTT

$ -*
/
'>
6 /
*!
0. @ / -- )/
*-(0'/$*)
*!
34*)/$)>


)"'


VTUV<
WZ[=U\[@U\]
.$)
U]]Y;
(*./'4
!-*(
34*)/$) 
)
 ;
>
#
+-*(*/$*)
)
(-& /$)"
*!
*34*)/$)=
*(( -$'
/-$0(+#;
+0'$
# '/#
/-" 4>
-
-
!
 
>>0
VVUHVV[
LVTT]M>   
 $- /@*@#4.$$)
)
$- /@*@*).0( -
-& /$)" 
 -/#0-
&' - (+' .=
R[;]TT;TTT;TTT
=
RV;YTT;TTT;TTT

 
!
 #
8<:<.8<;9 #4.$$)=
RX;TTT;TTT;TTT    $5 +(
L'$0(M

 1 -/$.
$)

U]ZW - +- . )//$1 .
( /
2$/#
+#4.$$). U][\ U]\X U]][ VTTT RZTT;TTT;TTT

*)/$) 
$)
- 1 )0
LU][\M  $'
 1 -/$.$)"
''
*!
( =
-/#0-
&' -

''*2.
3+).$*)
*!

)1 )/*-
*!
'$0(;
)
/#
*./
!/ )
- .-$
-0";
$ .>
.#$)"/*)
*./>
/* -
U;
VTTY>

(-& /$)"  '' ;
>
>
:
4' .;
>
>
$- /@/*@*).0( -
 1 -/$.$)"
*!
+#-( 0/$'.>
-
-
-
8970
X[YH\T
LVTT[M> )"
-
L M>

1 -"
)"/#
*!
$.$/=
UW
($)0/ . #4.$$)
4( )/ $- /
4( )/
/*
#4.$$).=
/0- .;
*)/$)0$)"
 $'
 0/$*);
-*(*/$*).>


- ..
) 4
/$ )/
/$.!/$*)
0-1 4.

*)9$/
*!
$)/ - ./B


)
/-).+- )4>
*.+$/'
*).0( -
.. ..( )/
*!
'/#-
-*1$ -.
)
4./ (.
L  M VTUTI
#4.$$)
4( )/.
0).#$)
/=

#//+.=GG222>(.>"*1G*+ )+4( )/.G Norman Rockwell. The Doctor and The Doll. 1929.  !
"
"
'
  !
"
"
 


   
 

 "

  


01+
*0.$*00
%+)*-& The Saturday Evening Post

#
*-'
'/#
-")$./$*)D.
) -
 -
LU]\ZM #
Y/#
$/'
$")
LU]]ZM

#
( -$)
$)
*$ /4
LM
- .$ )/;
->
( .
(+ '';
$)
U]]Z
.$ ;
1

#
  
# 


&

 

5" 6
*

#!
"

!
 



 
%-




 

! 





" 
-2 =
W[>T

=
]Z

=
UW]G\W
=
U\
$)=
[
#
$)/ )/$*)
/*
$(+-*1
2- ) ..
)
- 0
.06 -$)"
2.
)*/
2-*)">

#
 / -).
'/#
 ($)$./-/$*)
 *+/.
/#
Y/#
1$/'
.$")
$)
U]]\> #
*$)/
*(($..$*)
*)
- $//$*)
*!
'/#-
-")$5/$*).
L  M;

U]\Z U]]Z )*2
''
#
*$)/
*(($..$*)
$)/-* 0 .
/#
./) -
$)
VTTT>

#
$)/ )/$*)
*!
/#
 
)'" .$
 -
2.
/*
+-*(*/
/#
#
*.+$
*1 ( )/
L/#
U]]T.M 0.
*!
)'" .$.
!*-
) -
+$)
$)
- .
/#/
$
)*/>


1



 &




 

"


 
#

%
!'
!" 
-

 
!
%


  



+
#
! 
 %*




 




<7=

  -2

#
++'$/$*)
#.
*!/ )
'*./
$/.
-/$*)'
*-$"$)> >>
 $'
 0/$*)
*)
$)
:
+$*$ . #4
.
+$*$ .
!*-
$)B

#
1 -"
)0( -
*!
#*0-.
1*/
/*
+$)
0/$*)
$)
( -$)
( $'

-
'$($/
4
2#$#
( $/$*).
2
#1
$)
*0-
)'" .$
-(( )/-$0(=
.#**'.
*1 -
X
4 -.
$.?
J /($)*+# )G- /(*'
J4'*@34" ).
)#$$/*-.
L .M
J 0+-*! )
J +-*3 )
]
#*0-.>
J  '*3$(
J $'*! )
J  ' *3$
4
/#
/$(
4*0
7)$.#
/#
.# -
$)$
 $'
#**'
' /0- .
*)
$)
J+ )/$)*$ .
J + )/$)
 0/$*)
!-*(
-.>
#0(# -;
0''$).;
*- ;
 4;

$)/*;
)
(4. '!;
J - "'$)
4*0
2$''
#1
-  $1 ?
J@  +/*-
)/"*)$./.
J /($)
J  !*+(
J ") .$0(
Z
#*0-.
*!
$ /$.
)
W
#*0-.
*!
:?
]
#*0-.>
J  ()/$)
J'+#@V
"*)$./.
J '*)$ $)
*)"-/0'/$*).A
J  3( /*($ $)
J ' /$1
*- +$) +#-$)
 0+/&
)#$$/*-.
 

 > J *'
) ./# /$.
!*-
4./ ($
)
 "$*)'
)'" .$
J $ *$)
J 0+$1$)
J *+$1$)


SU=
# -
$.
)*
 $'$)"
6 /
2$/#
*+$*$ .

SV=
+$*$ .
-
'24.
/#
(*./
6 /$1
/- /( )/
*!
+$)

+$*$ .
-
*)'4
6 /$1
!*-
)'" .$
.*(
+ *+'
$)
 -/$)
.$/0/$*).>
J0/ ;
. 1 - ;
- &/#-*0"#
+$);
/# 4
-
" ) -''4
 +/ >
J) -
+$);
+''$/$1
- ;
) @*!@'$! ;
/# 4
-
" ) -''4
 +/ >
J# $-
0.
$)
#-*)$
)*)@) -
+$)
$.
*)/-*1 -.$'>


)'" .$.
#1

 $'$)"
6 /I
/#$.
$.
/#
+*$)/
/
2#$#
$)- .$)"
*. .
+$*$ .
-
0. !0'
!*-
 
+$);
)
' ..
.*
!*-

+$)
'  .
/*
)*
 // -
- .+*).
L)'" .$M>


*0
)
*)'4
" /
.*
(0#
- '$ !
2$/#
 /($)*+# )
L4' )*'M
+$*$ .
1-4
*)
/# $-
+#-(*&$) /$.
)
+#-(* 4)($.
(&$)"
- .+*). .
1-$' >

0-/# -(*- ;
#
$) $1$ 0'
#.
1-$'
-  +/*-.
)
/
++ -
/#/
*+$*$ .
#
)*
 $'$)"
6 /?
0/
/#
 $'$)"
$.
,0$/
#$"#>
- .+*)
$6 - )/'4
/#
6 /.
*!
*+$*$ .
!-*(
)
)'" .$
)
+.4#*'*"$'
./) +*$)/>

*-
3(+' ;


.
/#
 $'$)"
6 /
*!
*+$*$ .
1 -4 4
/
>
0-- )/'4
$)
( $$) ;
2
-
./$''
0.$)"
/-$'@) @ --*-
/*
/ -($)
/#
-$.&G  ) 7/
+-*7' >

@ )#$$/*-.
L*)@/ -*$ '
)/$@ )9((/*-4
-0".
`
 .M
/0''4
-
(*-
6 /$1
$)
0/
+$)>

# 4
#1
/# $-
-$.&.
/**?

3!*-
"0
'
*!
)'" .$
84>
) *'$ ->) / 
SW=
*0
%0./
#1
/*
2*--4
*0/
/#
0/
6 /.?
+$*$ @ ) 0
4+ -'" .$
L M

#$.
$.
/#
)*/$*)
/#/
*+$*$ .
/0''4
(&
4*0
 
  

>




 


 
#
7-./
'$)$'
*) +/
2.
- *")$5
4
) ./# .$*'*"$./.
2*-&$)"
2$/#
)

   
 *+$*$
''
- ($! )/)$';

-+$ '4@( /*'$5
*+$*$ ;
/#/
2.
0.
0-$)"
.0-" -4>

 
 
 
)$('
./0 $ .
!-*(
/#
'/
U]]T.
VTTT.
#1
G  
 
*)7-(
/#$.
+# )*( )*)
)
1 -4
*+$*$
#.
 

 





























 )
$(+'$/
/*
1-$*0.
"- .>


  
)
" ) -';
/#
+# )*( )*)
$.
(*./
+-*)*0)
2$/#




  
*+$*$ .
2$/#
/#
.#*-/ ./
*6. /;
2$/#
#$"# -
*. .;
 
 
  
)
'*)" -
0-/$*)
*!
0. >

  
 ;


 
;
  
 
  

$.
/#
- .*)

*
)*/
- *(( )
*+$*$ .
!*-
#-*)$
)*)@) -
+$)>

   
 
  
   0-
*)'4
&)*2)
( /#*
/*
 - ..

0-- )/'4
$.
/#
0.
*!

)/"*)$.(I
& /($) ;
(") .$0(;
)$/-*0.
*3$ ;
( ()/$) ;
/?

-*(
*-+#$)
/*
 /./.$.
-$1$)"
#$'
*)
- .-$+/$*)
+$*$ .
$.
-0""
-$1$)"



UY
>


 
 UY >

;
;
;
;
;
 ;
;
;
;
 ;
;
 ;
;
;
 ; ;  ; ;
;  ;  ; ;;

; ;   ;;

;;
 ; ;
; ;;


  >



  

   >
 
     
)
'$!*-)$;

+ ) ) ''''$$!*$!!*!*-)$-)-))$;; 
++
+ --.-.*)
$.
"0$'/4
*!

$!
#.**)) $.$$.
..

""$"0$"000$$'/4'/'//44 *!*! 

$!!#!
#!
#
*

*-
.#*--.-
..#

$.
LUM
-$.$$.
..
LLUMLUUUMM - -$1$)"
0) $$$1$$$11$1$))")"
" 0)0) 0)) --
-
/#/#/#
$)90$)$)9090 ))
*!
)4
*!*! ))4
4 '''*#*'$
''*#**#*##**'$$  1 --"""
*-
-0";

LVM
-$1$)"
2#$'*-*- --0"00";"";;  LLVVMM M

-$--$1$$11$$)$)")")" 22##$$''
 $/  $ $$$/ /
/*

//**  -0 - -0">
'>
-0-0">">
">>
''''>>
>
>
 #>##>
* > **

OO
OOOOO
OO
VWUVWUYVLM;LM>UYVLYVVLLM;MM;;LLLMLMMM> *2
*
2
- *)$'
/#
/$ )/@*/*-
 '/$*).#$+
2# )
$/
*( .
/*
*+$*$ .B
1) Place patient label at the bottom of this document. 2) In Apex, under Problem List, state that the patient has an Opioid Ag

PEDIATRIC PATIENT PROVIDER PATIENT PROVIDER AGREEMENT AGREEMENT ON OPIOID THERAPY PATIENTON OPIOID PROVIDER THERAPY AGREEM




 


 
 









Purpose: The purpose of this agreement is to protect your access to controlled substances and to




  

 


protect our ability to prescribe for you/ your child. This agreement is reviewed    continuously and signed by patients/guardians in our practice. 1(
!
" 
 

 
$!
 $


  


 $
 !


1. Your provider has determined that you/your child may be a candidate for opioid therapy because of  


  
 
 )
"
! (
their potential benefits to decrease pain and/or improve function. 2(



" 

# 
 $




!
!

 (





 $
2. There are several risks and side effects which may limit or end the continued use of opioids. Risks of  ! 
!



'
opioid therapy include but are not limited to: Respiratory Depression Sweating Low Testosterone Hives Itching Potential for Addiction Worse Pain Over Time Sudden Death Risk of Death with Obstructive Decreased Immune Irregular/Absent Inability to Control Pain with Increasing Constipation Potential for Abuse Sedation/Sleepy Risk of Death with Obstructive Sleep Apnea Sleep Apnea Function Menstruation Doses of Opioids (Tolerance) +$*$
/$ )/
-*1$ -
"- ( )/.
Nausea/Vomiting Low Testosterone Seizures Inability to Control Pain with Increasing Doses of Opioids Nausea / Vomiting Constipation Tremors Altered Mental Status Sweating Confusion Ability to Complete Suicide Risk of Others Using/Stealing Your Drugs Potential Harm to Unborn or Worse Pain Over Time Decreased Bone Risk of Others Using/Stealing Your Drugs 
$.0..$*)
*0/
-$.&.
)
 ) 7/.>


Newborn Baby (if breastfeeding) (Hyperalgesia) Density Hives Tremors Withdrawals Arrhythmia (unique opioids) Itching Weight Gain Withdrawals Arrhythmia (unique opioids) Weight Gain Irregular/Absent Impairment While Driving *Mixing with Alcohol or Other Drugs increases many of the Menstruation other risks listed Impairment while Driving or Depressed Mood Potential for Addiction *Mixing with Alcohol or Other Drugs Operating Machinery increases many of the other risks listed Depressed Mood Decreased Immune Respiratory Depression Potential Harm to Unborn or Newborn Baby (if breastfeeding) *0
./$''
#1
UW
($)0/ .
.*
/#
( .."
#.
/*
*(
!-*(?
Function Seizures Potential for Abuse Sudden Death Drowsiness 3. Patient/guardian will allow the provider to communicate about treatment with all other medical and 3(
!
#
#
$!
" 

! 
!
 
#


  

 
 
mental health providers. $.&
.. ..( )/
**'.
" (
4. Patient will only receive opioid prescriptions from this clinic, and guardian will inform the provider of 4(

!
#
$
 "


 


 &

#

$!
" 

$
any medication changes of any kind. - ) -
)
+$*$
.. ..( )/
!*-
/$ )/.
2$/#
$)
@
 1$.
L@M
  
 

$
 (
5. Patient’s guardian is responsible for safeguarding medications. Lost, misplaced, or stolen J 5(

!

 

 !  
  (

&
  &


 

  
prescriptions or medications may not be replaced and may result in discontinuation of opioid therapy.  $


 

 $
!

 ! 


 $(
6. Any evidence of drug hoarding, taking any other pain medications from other physicians (including the emergency room), changing the dose, or not following this agreement may result in discontinuation of 6(
!
#
 
 

  



 



 !
#
" (

 $
!
J0-- )/
+$*$
$.0.
 .0-
LM
opioid therapy. 

 $


 








 (
reement. 3) Scan this document with signatures and label into Scanned Clinical Documents. 7. Patients will take opioids as prescribed, under the guardian’s direct supervision. Early request for J$)
.4#*'*"$./.
7(


 "
 


, $&
 &
"&--
#






"
 refills may not be permitted. (

!
" 
 
$!


8. Patient may not share opioid medication with friends, family, or others


 !

 

  

#'
9. Patient/guardian is expected to return to clinic as instructed by the provider for frequent follow up.


















































  

  

 
  
 
10. Provider may do routine drug screening to ensure safe use of the medication. Higher dose and high risk - .-$+/$*)
-0"
*)$/*-$)"
-*"-(.
8(

 $

!
!
 

!
 
!


   !       (




*
   * behavior (drinking alcohol, using other drugs, early refill requests, failing to submit or tampering with  "
, 
 &
!

!&
 $

!&
 

! 

 
#
urine) should result in more frequent testing. !-
 $
!


!
(


11. Provider may invite patient with high-risk behavior to come for more frequent clinic visits and/or to -$)
-0"
- )$)".
10(

 $
"
$!





!

"
 )

!
(

 !




count pills. Failure to bring in appropriate number of pills would demonstrate that the risk of continuing  
! 


 $
 
 



!


 $

(
chronic opioid therapy is high. 10(

#
! $
" ! 

)
 


 $(
12. Patient will agree to psychological assessment as part of opioid therapy. 11(
 
 

 
 

 

 



  
 
 

 
13. Provider may taper off opioids if they are no longer controlling pain or improving function, if side # -
/*
 /0-)
)0.
-0".>
*'$
//$*).;
#-($ .>
effects are severe, if appointments are frequently missed, if behavior is high-risk, or if this agreement is

!
" 
 $
 "
 
 

!!
! 
#

 $
#

! (
not followed. The provider may decide that if risks outweigh benefits at any time, opioid therapy will be discontinued. We will continually evaluate the benefit/risk ratio of this therapy. *&
+
-0".
/
*( >



 
 


 >
 
 
 


  



 

 

______/___/______/___/____ ++++++++++++++++++++++++++++++++)+++)+++

+++++++++++++++++++++++++++++++++)+++)++++
signature of patient date signature of provider date  ..
/*
'*3*)
  

 









  





______/___/___ Patient Label signature of guardian  
,(+(
"! 
%
 (
!!
! '
 (
 
!'
 (
$ 
 '
!
"!
'
'
 (

"(

) 
-+,.*
 #
%


!!'
"
,/'
-+,.
 #
%

&
!!
!
-+,.(

DRAFT 
% $












!
&$%'"


 


######

ORAL PARENTERAL (mg) (mg) *) -)$)"
*+0'/$*).=
- "))4

DRUG   ,) *)  
 , ,) # (  ,) # ( 

-( .-( . ,) # '( +) 10 '(

- '(". +) - (  
-$. /". *". - "))4
(  

-'. /". #  
- ./ ,)) *)) // +)) 100 '(
- %./// +)) - '( 
- . *) * '( 

- 
 . *) - %  -+ !(
-$). - )"* !(

-$  . 
  
    
-! . *+) 100  

-! 
 . *+) - !
- $(!. *+) - !

- $(!
 . *+) - $  
-$$!'. )"-
%  & )", $  

-$!  . 
  
  
$
- $. - *) '+' ..
)
**& >
 0/ -.>
 
[;
VTUY
!)
-&. - ,) 06
$'.*)
)
*#)
#$6() *) -)$)"
*+0'/$*).=
#$' - )
 )5* $5 +$) .=
#
$./ -
$' )/
+$ ($  )5* $5 +$) .  /#.
+ -
UTT;TTT
+ *+'
$)
/#
)$/
// .

!-*(
VTTT@VTUX
 )/ -.
!*-
$. .
*)/-*'
:
- 1 )/$*)

*$)

*/

"**
#*$
!*-
'*)"@/ -(
.' +
$ >
$.-0+/.
.' +
-#$/ /0- >

3*" )*0.
@
"*)$./.
1.
) *" )*0.
.4./ (
*/

"**
#*$
!*-
'*)"@/ -(
)3$*'4.$.>
4

0. !0'
!*-
.#*-/@/ -(
)3$*'4.$.
)
$)
.+ $7
.$/0/$*).

 .+$-/*-4
+- ..$*)
!-*(
*+$*$ .
_
 )5* $5 +$) .
$.
.4) -"$./$


)3$ /4
.+ $'$./.
L+.4#$/-$./.M
)
.' +
.+ $'$./.
L+0'(*)*"$./.G) ./# .$*'*"$./.M

!
2 ;
/#
( $'
*((0)$/4
L"*1 -)( )/;
$).0- -.;
+-*1$ -.M
./-/

(0./
. /
)
3(+'
!*-
*/# -
*0)/-$ .> /*
'$($/
/#
 ..
*!
*+$*$ .
/*
$) $1$ 0'.;
L2#$#
$.
)*0-" M;
$/
2$''
' 

)0( -
*!
$) $1$ 0'.
/*
/0-)
/*
$''$$/
*+$*$ .
$)'0 $)"
# -*$)>

*)% /0-
/#/
+- .-$+/$*)
*+$*$
- '/
/#.
2$''
./-/
/*
+'/ 0
$!
)*/
- .
)
# -*$)@- '/
/#.
2$''
$)- . >

0. @ / -- )/
-0".
(4
# '+;
0/
-
)*/
/#
).2 ->


)
/*
+- +-
*0-
*0)/-4
*)
#*2
/*
'
2$/#
*1 - *. ;
2$/# -2'.;
0. ;
)
 $/$*)>

4  
"
 
5 




  6
4 
$

4 $
 LEGISLATIONPUBLIC AWARENESS +
 ./-$/$*).
&"$)"
 ./-$/$*).
:
-)$)"
 '.
)- .$)"
/3 .
*)
$"- // .
HEALTH CARE PUBLIC LEGISLATION PATIENT DISRUPTIVE PROVIDER AWARENESS ACCESS & TECHNOLOGY $.$$'$/4
*!
(*&$)"
$)
)/ -/$)( )/
EDUCATION & EDUCATION ACCOUNTABILITY )
-)$.*
$.
$)- .$)"
"
($)$(0(
!*-
+0-#.
!-*(
U\
/*
VU
4 -.

PATIENT ACCESS & EDUCATION  ..
/*
+-*"-(.
.0#
.=
U@\TT@*@

HEALTH CARE PROVIDER EDUCATION & - )$)"
ACCOUNTABILITY  )$)"!0'
.

PUBLIC AWARENESS  - .
$)
(*&$)"
/ .=
U][Y@) -
+- . )/ #'( ()(
$
  #
%$&(
#
9788

UUZ
($''$*)
( -$).
#1
#-*)$
+$)

#-*)$
+$)
*./.
RZWY;TTT;TTT;TTT
))0''4
$)
# '/#
-
)
'*./
+-* 0/$1$/4

#/
$.
(*-
/#)
/#
*($)
*./
*!
# -/
$. . ;
$ / .;
)
) -

#
'/$(/
$60.$*)
*!
 .+*).$$'$/4>

#
)$/
// .>

Government Doctors Health and Human Research Services Organ-Based      Centers for Disease Specialists 
''
#1NIH-Brain

- .+*).$$'$/4 Control and Prevention NIDA Food and Drug Generalists without Administration Expertise or Resources Pain Research? Drug Enforcement Agency Pain Specialists Pain Agency? #)&
*0

->
-&
#0(# -
 )/ -.
!*-
$. .
*)/-*'
)
- 1 )/$*)
$)
#4.$$).
2#*
2)/
/*
(&

$6 - )
$)
 . -# -.
2#*
2)/
/*
(&

$6 - )
0/#*-.
2#*
2)/
/*
(&

$6 - )
J(
0$)*) .
- (')
J 0 4
*- ()

/$*)
)
$)
J ')$
# -)./-*(
#
$)
#-*)$' .

U> /$*)'
)./$/0/
*)
-0"
0. >
LVTUYM>
-0".
*!
0. =
+$*$ .>
 /# . ;
=
/$*)'
)./$/0/
*)
-0"
0. >
1$''
/
#//+=GG222> -0"0. >"*1G -0".@0. G *+$*$ .>
V> ( -$)
*$ /4
*!
 $/$*)
 $$) >
LVTUUM>
0'$
*'$4
// ( )/=
 7)$/$*)
*!
 $/$*)>
# 14
#. ;
=
( -$)
*$ /4
*!
 $/$*)
 $$) >
1$''
/
#//+=GG222>.(>*-"G *.G+0'$4@
+*'$4@.// ( )/.GU 7)$/$*)P*!P $/$*)P'*)"PX@UU>+ !B.!1-.)`V>
W> 0./)
0.
)
 )/'
'/#
 -1$ .
 ($)$./-/$*);
 )/ -
!*-
 #1$*-'
'/#
//$./$.
)
0'$/4>
LVTUYM>
 #1$*-'
# '/#
/- ) .
$)
/#
)$/
// .=
 .0'/.
!-*(
/#
VTUX
/$*)'
0-1 4
*)
-0"
.
)
'/#>
*&1$'' ;
=
0./)
0.
)
 )/'
'/#
 -1$ .
 ($)$./-/$*)>
1$''
/
#//+=GG 222>.(#.>"*1G /G.$/ .G !0'/G7' .G @U@VTUXG @U@VTUX>+ !>

X> /$*)'
)./$/0/
*)
-0"
0. >
LVTUXM>
-0"
/.=
-*$)>
 /# . ;
=
/$*)'
)./$/0/
*)
-0"
0. >
1$''
/
#//+=GG222> -0"0. >"*1G+0'$/$*).G -0"!/.G# -*$)>
Y>  )/ -
!*-
$. .
*)/-*'
)
- 1 )/$*);
/$*)'
 )/ -
!*-
'/#
//$./$.;
/$*)'
$/'
//$./$.
4./ (;
*-/'$/4
$' >
LVTUYM>
0( -
)
" @ %0./
/ .
*!
-0"@+*$.*)$)"
 /#.
)1*'1$)"
+$*$
)'" .$.
)
-*$)=
)$/
// .;
VTTTHVTUX>
/')/;
=
 )/ -
!*-
$. .
*)/-*'
)
- 1 )/$*)>
1$''
/
#//+=GG 222> >"*1G)#.G /G# '/#P+*'$4GP -0"P+*$.*)$)"P$)1*'1$)"PP -*$)PPVTTT@
VTUX>+ !>
Z> 0'*55$
;
*) .
#-(;
&
#;
0
 >
$/'
$").=
1 - *. .
*!
- .-$+/$*)
+$*$
$)
 '$ 1 -.
H
)$/
// ;
U]]]@VTT\>
$1$.$*)
*!
)$)/ )/$*)'
)%0-4 - 1 )/$*);
/$*)'
 )/ -
!*-
)%0-4
- 1 )/$*)
)
*)/-*';
 )/ -
!*-
$. .
*)/-*'
)
- 1 )/$*)>
VTUU=ZT=Y>
[>  )/ -.
!*-
$. .
*)/-*'
)
- 1 )/$*)>
LVTUXM>
+$*$
$)&$'' -
- .-$$)";
# -
*0
$1
& .

$6 - ) >
/')/;
=
 )/ -.
!*-
$. .
*)/-*'
)
- 1 )/$*)>
1$''
/
#//+=GG222> >"*1G1$/'.$").G*+$*$ @+- .-$$)"G>
\> "-

 ;
# )

#;
-) -
#>
-0"@*$.*)$)"
 /#.
)1*'1$)"
-*$)=
)$/
// .;
VTTT@VTUW>
/$*)'
 )/ -
!*-
'/#
//$./$.
/
-$ !>
VTUY=U]T=U@\>
]> $ -*
 ;
''$.
;
0--//
;
0-/5
>
#
#)"$)"
!
*!
# -*$)
0.
$)
/#
)$/
// .=

- /-*.+ /$1
)'4.$.
*!
/#
+./
YT
4 -.>

.4#$/-4>
VTUX<[UL[M= \VU@\VZ>
UT> /$*)'
)./$/0/
*!
-0"
0. >
LVTUYM>
-0"
/.=
- .-$+/$*)
)
1 -@/# @*0)/ -
 $/$*).>
 /# . ;
=
/$*)'
)./$/0/
*!
-0"
0. >
1$''
/
#//+=GG 222> -0"0. >"*1G+0'$/$*).G -0"!/.G+- .-$+/$*)@*1 -@*0)/ -@( $/$*).>
UU> *-/0)
 ;
*$).
;
$*'
;
*4)/
;
'/ -()
>
- .-$$)"
*!
*)/-*''
( $/$*).
/*
 *' . )/.
)
4*0)"
 0'/.
$)
/#
)$/
// .>
 $/-$.>
VTUT
UV>  )/ -
!*-
$. .
*)/-*'
)
- 1 )/$*)>
LVTUWM>
- .-$+/$*)
$)&$'' -
1 - *. .=

-*2$)"
+$ ($;
.+ $''4
(*)"
*( )>
/')/;
=
 )/ -.
!*-
$. .
*)/-*'
)
- 1 )/$*)>
1$''
/
#//+=GG222> >"*1G1$/'.$").G+- .-$+/$*)+$)&$'' -*1 - *. .G$) 3>#/('>